Search Results
Mar 02, 2026, 09:00 ET Bulletproof™ Introduces Coffee + Creatine, a First-of-Its-Kind Functional Coffee Innovation
is a premium instant black coffee crafted with clean, toxin-tested 100% Arabica beans and 5 grams of creatine monohydrate per serving, along with 250 mg of electrolytes to support hydration and performance. The instant powder mixes easily into hot or cold water and brews into a smooth cup of coffee that
More news about: Bulletproof Coffee
Mar 02, 2026, 08:36 ET Aquafortus and GS E&C Sign Collaboration Agreement to Advance Secondary Battery Wastewater Treatment in the Republic of Korea
present increasing treatment complexity. These wastewaters often contain salinity levels reaching total dissolved solids concentrations as high as 150,000 mg/l and dissolved contaminants that challenge conventional membrane and thermal treatment systems. In water-constrained regions and highly regulated industrial
More news about: Aquafortus
Mar 02, 2026, 08:30 ET AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease
healthcare provider tells you to use it.SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.This is the most important
More news about: AbbVie
Mar 02, 2026, 07:00 ET Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis
Differences versus placebo were 38.1% (12 mg) and 46.4% (24 mg) (p < 0.0001).vIGA-AD 0/1 response: Improvements over placebo were 30.3% (12 mg) and 31.0% (24 mg) (p < 0.0001).WI-NRS4 response rates were 31.3% (12 mg) and 31.0% (24 mg) higher than placebo at Week 16 (p < 0.0001).Zemprocitinib
More news about: Lynk Pharmaceuticals Co., Ltd.
Mar 01, 2026, 19:00 ET Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
lymphocytic lymphoma (SLL). The trial enrolled 238 patients, who were randomized 1:1 to receive Jaypirca (200 mg orally, once daily) or investigator's choice of either IdelaR or BR per labeled doses. This trial's primary endpoint is progression-free
More news about: Innovent Biologics
Feb 28, 2026, 09:45 ET Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis
frequently reported across a range of symptoms, including GI, skin, abdominal pain and headache symptoms.Among patients who initiated the 25 mg daily dose of AYVAKIT (n=16), 87.5 percent have remained on therapy, reflecting a well-tolerated safety profile.An additional presentation features
More news about: Blueprint Medicines, a Sanofi company
Feb 27, 2026, 20:00 ET U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
pediatric patients 12 years of age and older with phenylketonuria (PKU) who have uncontrolled blood Phe concentrations greater than 600 micromol/L (10 mg/dL) on existing management.BOXED WARNING: ANAPHYLAXISAnaphylaxis has been reported after administration of PALYNZIQ
More news about: BioMarin Pharmaceutical Inc.
Feb 27, 2026, 15:51 ET FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications
with SGA were randomized to Sogroya® 0.24 mg/kg/week (n=70), once-daily somatropin 0.035 mg/kg/day (n=37), or once-daily somatropin 0.067 mg/kg/day (n=35). Dose of 0.035 mg/kg/day of daily somatropin is less than maximum dose (0.067 mg/kg/day) approved for use in pediatric patients with SGA in
More news about: Novo Nordisk
Feb 27, 2026, 11:44 ET Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
enrolled 34 participants across three clinical sites in the United Kingdom.The study met its primary endpoint. Participants receiving a single 21.5 mg dose showed a mean MADRS difference of -7.35 versus placebo (p=0.023), with effects appearing within one week (p=0.002).Response rates at two
More news about: Equity Insider
Feb 27, 2026, 11:28 ET Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy
subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single–patient–use prefilled pens, the generic equivalent of Saxenda® (liraglutide injection).
More news about: Cipla USA Inc.
Feb 27, 2026, 10:24 ET Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami
Full Prescribing Information.About LEQSELVI™ and alopecia areataLEQSELVI (deuruxolitinib) 8 mg tablets is an oral selective inhibitor of Janus kinases JAK1 and JAK2 approved for the treatment of adults with severe alopecia areata. Alopecia areata
More news about: Sun Pharma
Feb 27, 2026, 10:00 ET SYSTM Foods Brings Bold Innovation to Expo West 2026 with Debut of REBBL Clear Protein Beverage
Benefits:20g of non-GMO whey proteinZero sugar & just 80 caloriesEssential electrolytes including 300mg potassium, 100mg magnesium, 95mg sodiumZinc for immune supportIn addition to REBBL's latest innovation, SYSTM Foods will sample Humm Nitro (MSRP:
More news about: SYSTM Brands
Feb 27, 2026, 09:42 ET PharmaGiant.com Expands Access to Affordable Medications; Announces Upcoming Generic Semaglutide
Rosuvastatin 5mg (30 tablets): $30 at PharmaGiant vs. $136 U.S. retail.Amlodipine 5mg (100 tablets): $58.95 at PharmaGiant vs. $117.14 U.S. retail.Atorvastatin 10mg (90 tablets): $24 at PharmaGiant vs. $271 U.S. retail.Metformin 500mg (100 tablets):
More news about: PharmaGiant.com
Feb 27, 2026, 08:11 ET Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
to receive once-daily placebo, Olumiant 4 mg or Olumiant 2 mg. The primary endpoint of this study was a SALT score ≤20 (i.e., 80% or more scalp hair coverage) at Week 36. The second cohort of 166 adolescents were randomized 1:1 to Olumiant 4 mg or Olumiant 2 mg to further accumulate safety data.The
More news about: Eli Lilly and Company
Feb 27, 2026, 07:28 ET Rare Cannabinoid Company Expands Mood Collection with New THC-Free CBC Gummies with CBC and CBD
Gummies (15mg CBC + 15mg CBD)The newly released, all-natural, vegan, lime and mint flavored CBC Gummies were formulated to spotlight cannabichromene as the primary active cannabinoid.Each gummy contains:15mg cannabichromene (CBC)15mg CBD0mg
More news about: Rare Cannabinoid Company
Feb 26, 2026, 15:34 ET Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
36-week treatment period. Approximately 160 participants with ALS will be randomised to receive either daily NUZ-001 at the recommended Phase 2 dose of 10 mg/kg or placebo at a 3:1 ratio. The primary objective is to evaluate the efficacy of NUZ-001 compared with placebo on ALS disease progression, with secondary
More news about: Neurizon Therapeutics Limited
Feb 26, 2026, 12:39 ET Liderada pelo empresário Lucas Kallas, Cedro Participações vai investir R$ 5 bi em projetos de logística
deve gerar R$ 1,2 bilhão em Imposto Sobre Serviços (ISS) para os municípios da região.Já com a ampliação da operação de Mariana (MG), a empresa projeta o recolhimento de R$ 350 milhões em tributos e R$ 100 milhões em Compensação Financeira pela Exploração de Recursos Minerais.
More news about: Cedro
Feb 26, 2026, 12:07 ET Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
enrolled 34 participants across three clinical sites in the United Kingdom.The study met its primary endpoint. Participants receiving a single 21.5 mg dose showed a mean MADRS difference of -7.35 versus placebo (p=0.023), with effects appearing within one week (p=0.002).Response rates at two
More news about: USA News Group
Feb 26, 2026, 09:12 ET Herbs, Etc. Launches ChlorOxygen® Lemonade Powder, Bringing Its #1-Selling Chlorophyll to a Convenient, On-the-Go Format
powder designed to fit modern, on-the-go lifestyles.The new ChlorOxygen® Lemonade Powder format delivers:50mg of chlorophyll3 grams of dietary fiber per servingNo sugar100% vegan ingredientsSingle-serve stick packs for portability"Consumers
More news about: Herbs, Etc.
Feb 26, 2026, 08:01 ET Durin Selects Silicon Labs' MG24 Wireless SoC to Accelerate Aliro Mobile Access for Smart Locks and Readers
Colin Cureton, Vice President of Product Lines, Home, Silicon Labs. "MG24 gives innovators like Durin a single, secure wireless platform to validate credentials, protect keys, and do all this at the speed end-users demand thanks to the MG24's cryptography accelerator. As the industry rallies behind Aliro,
More news about: Silicon Labs
Feb 26, 2026, 08:00 ET Introducing Aliro 1.0: A Unified Standard to Transform the Access Control Ecosystem
the homeowner's mobile wallet and their smart door lock. MG24 gives innovators a single, secure wireless platform to validate credentials, protect keys, and do all this at the speed end-users demand thanks to the MG24's cryptography accelerator. As the industry rallies behind Aliro, Silicon
More news about: Connectivity Standards Alliance
Feb 26, 2026, 06:30 ET Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
study at a dose of orforglipron 1 mg once-daily and then increased the dose in a step-wise approach at four-week intervals until reaching their randomized maintenance dose of 12 mg (via steps at 1 mg, 3 mg and 6 mg) or 36 mg (via steps at 1 mg, 3 mg, 6 mg, 12 mg and 24 mg). All participants in the oral semaglutide
More news about: Eli Lilly and Company
Feb 26, 2026, 05:40 ET CJ BIO Publishes Clinical Study on BiomeNrich™ POST SZ075, a Postbiotic Ingredient Demonstrating Skin Improvement Benefits
elasticity and dermal density.Dual-Action Efficacy of BiomeNrich™ POST SZ075 for Skin Health A clinical study (n=111, 12 weeks, 500 mg/day) published in Food Science and Biotechnology (2025) confirms the dual functionality of BiomeNrich™ POST SZ075 in combating UV-induced wrinkles and enhancing
More news about: CJ CheilJedang
Feb 25, 2026, 21:00 ET Argo Biopharma to Present Positive Phase II Interim Results of siRNA Therapeutic BW-20805 for HAE at the 2026 AAAAI Annual Meeting
100% in the 600 mg Q24W group, 89% in the 300 mg Q24W group, and 87% in the 300 mg Q12W group. Additionally, 80% (8/10) of treated patients remained attack-free.Plasma PKK levels showed a rapid and profound decrease. On Day 85, in the pooled 300 mg groups (Q24W and Q12W),
More news about: Argo Biopharmaceutical Co., Ltd
Feb 24, 2026, 16:03 ET Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
discuss any questions you have with your doctor.Dosage Form and Strengths: IMAAVY® is supplied as a 300 mg/1.62 mL and a 1,200 mg/6.5 mL (185 mg/mL) single-dose vial per carton for intravenous injection.ABOUT JOHNSON & JOHNSONAt Johnson & Johnson, we
More news about: Johnson & Johnson